Invitae Corporation

Equities

NVTA.Q

US46185L1035

Biotechnology & Medical Research

End-of-day quote OTC Markets Other stock markets 03:30:00 16/07/2024 am IST			5-day change	1st Jan Change
0.0003 ^USD	-40.00%		-72.73%	-99.95%

13/06	First Amended Disclosure Statement Approved for Invitae Corporation	CI
11/06	Motion for Exclusivity Period Extension Approved For Invitae Corporation	CI

Invitae Corporation Reports Preliminary Unaudited Revenue Results for the Full Year 2020

January 11, 2021 at 06:00 pm IST

Invitae Corporation reported preliminary unaudited revenue results for the full year 2020. The company generated revenue of more than $278 million in 2020, an approximate 28% increase from $217 million in 2019 .

Latest news about Invitae Corporation

First Amended Disclosure Statement Approved for Invitae Corporation	13/06	CI
Motion for Exclusivity Period Extension Approved For Invitae Corporation	11/06	CI
First Amended Joint Liquidation Plan and Disclosure Statement Filed by Invitae Corporation	11/06	CI
North American Morning Briefing : PCE Inflation -2-	28/05	DJ
First Motion for Exclusivity Period Extension Filed by Invitae Corporation	21/05	CI
Joint Liquidation Plan and Disclosure Statement Filed by Invitae Corporation	09/05	CI
Motion for Asset Sale Approved for Invitae Corporation	07/05	CI
Labcorp beats quarterly estimates on strong testing demand	25/04	RE
Clinical lab operator Labcorp to buy bankrupt genetic test maker Invitae for $239 mln	25/04	RE
Laboratory Corporation of America Holdings (NYSE:LH) won the bid to acquire substantially all of the assets of Invitae Corporation for approximately $240 million.	24/04	CI
Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation (OTCPK:NVTA.Q).	24/04	CI
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance	11/04	CI
Invitae Launches Update to Invitae Generation: Clinical Variant Modeling Improves Variant Classification	12/03	CI
Earnings Flash (NVTA) INVITAE CORPORATION Posts Q4 Revenue $127.8M	06/03	MT
Invitae Corporation Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023	06/03	CI
Bidding Procedure Approved for Invitae Corporation	16/02	CI
Motion for Joint Administration Approved for Invitae Corporation	16/02	CI
Invitae gets court approval for five-month bankruptcy sale	16/02	RE
Global markets live: Airbnb, Sony, Uber, Lyft, Nvidia...	14/02
Genetic test maker Invitae files for bankruptcy protection in US	14/02	RE
Motion for Asset Sale Filed by Invitae Corporation	14/02	CI
Invitae Corporation Lists Estimated Assets In The Range Of $500 Mln -$1 Bln - Court Filing	14/02	RE
INVITAE CORPORATION LISTS ESTIMATED LIABILITIES IN THE RANGE OF…	14/02	RE
Genetic test maker Invitae files for voluntary Chapter 11 protection	14/02	RE
Motion for Joint Administration Filed by Invitae Corporation	13/02	CI

Chart Invitae Corporation

Duration

Period

More charts

Company Profile

Invitae Corporation is a medical genetics company. The Company is engaged in delivering genetic testing services, digital health solutions, and health data services that support a lifetime of patient care and improved outcomes. It offers genetic testing across multiple clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases and pharmacogenomics. It applies proprietary design, process automation, robotics and bioinformatics software solutions to expand the use and impact of genetic information in sample processing and complex variant interpretation, allowing medical interpretation at scale. The Company also utilizes digital health solutions to improve ease-of-use and to deliver actionable information about risk, prevention, treatment, and monitoring. The Company has served over 3.6 million patients, and over 2.2 million of those patients have made their information available for data sharing.

Sector

Biotechnology & Medical Research

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
INVITAE CORPORATION	-99.95%	85.95K
EXACT SCIENCES CORPORATION	-32.86%	9.17B
GUARDANT HEALTH, INC.	+25.06%	4.14B
IOVANCE BIOTHERAPEUTICS, INC.	+15.74%	2.63B
BGI GENOMICS CO., LTD.	-26.46%	1.85B
VERACYTE, INC.	-7.09%	1.95B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+40.61%	1.22B
CAREDX, INC	+54.75%	969M
SEEGENE, INC.	-9.17%	694M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-9.18%	656M

Bio Diagnostics & Testing